Skip to main content

Language: English / Gàidhlig

Loading…

Seòmar agus comataidhean

Questions and answers

Parliamentary questions can be asked by any MSP to the Scottish Government or the Scottish Parliamentary Corporate Body. The questions provide a means for MSPs to get factual and statistical information.

  • Written questions must be answered within 10 working days (20 working days during recess)
  • Other questions such as Topical, Portfolio, General and First Minister's Question Times are taken in the Chamber

Urgent Questions aren't included in the Question and Answers search.  There is a SPICe fact sheet listing Urgent and emergency questions.

Find out more about parliamentary questions

Criathragan Hide all filters

Dates of parliamentary sessions
  1. Session 1: 12 May 1999 to 31 March 2003
  2. Session 2: 7 May 2003 to 2 April 2007
  3. Session 3: 9 May 2007 to 22 March 2011
  4. Session 4: 11 May 2011 to 23 March 2016
  5. Session 5: 12 May 2016 to 5 May 2021
  6. Current session: 12 May 2021 to 21 April 2025
Answer status
Question type

Displaying 755 questions Show Answers

|

Question reference: S6W-29758

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Tuesday, 10 September 2024
  • Current Status: Answered by Neil Gray on 19 September 2024

To ask the Scottish Government what its response is to reports that NHS Western Isles has designated the refurbishment of Medical Ward 2 at the Western Isles Hospital in Stornoway as high priority, but that this work is reportedly unaffordable in the current financial year.

Question reference: S6W-29684

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe ocrelizumab (Ocrevus) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29629

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Siobhian Brown on 18 September 2024

To ask the Scottish Government whether it carried out an Island Communities Impact Assessment in advance of the reported end of grant funding agreements for advice services in the Western Isles on 31 March 2024, and, if this is not the case, for what reason.

Question reference: S6W-29681

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe fingolimod (Gilenya) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29680

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe diroximel fumarate (Vumerity) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29688

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe Rebif (beta interferon-1a) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29678

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe cladribine (Mavenclad) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29685

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe ozanimod (Zeposia) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29682

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe glatiramer acetate (Copaxone) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.

Question reference: S6W-29689

  • Asked by: Tim Eagle, MSP for Highlands and Islands, Scottish Conservative and Unionist Party
  • Date lodged: Friday, 06 September 2024
  • Current Status: Answered by Jenni Minto on 18 September 2024

To ask the Scottish Government which NHS boards prescribe siponimod (Mayzent) to treat multiple sclerosis (MS); how many patients in each NHS board are receiving this disease modifying therapy, and what its position is on whether it should be prescribed to appropriate patients.